JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, M.-S.
Right arrow Articles by Gold, B. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, M.-S.
Right arrow Articles by Gold, B. G.

Vol. 282, Issue 2, 1084-1093, 1997

Comparative Dose-Dependence Study of FK506 and Cyclosporin A on the Rate of Axonal Regeneration in the Rat Sciatic Nerve

M.-S. Wang, Michelle Zeleny-Pooley and Bruce G. Gold1

Center for Research on Occupational and Environmental Toxicology (M.-S.W., M.Z.-P., B.G.G.) and Department of Cell and Developmental Biology (B.G.G.), Oregon Health Sciences University, Portland, Oregon

The new immunosuppressant drug FK506 (Tacrolimus) increases the rate of nerve regeneration in vivo (; ). In the present study, we have examined the dose-dependence of FK506's ability to enhance nerve regeneration. In the first set of experiments, rats received daily s.c. injections of FK506 (2 mg/kg, 5 mg/kg or 10 mg/kg) for 18 days after a sciatic nerve crush injury. Signs of functional recovery in the hind feet appeared earlier than in saline-treated control rats at all three FK506 dosage; recovery was maximally accelerated in the 5-mg/kg group. Light microscopy at 18 days after nerve crush revealed more regenerating myelinated fibers in FK506-treated rats than in controls; this was most apparent in the 5-mg/kg group. Morphometric analysis of axonal areas in the soleus nerve confirmed that axonal calibers were maximally increased in the 5-mg/kg group. In the second set of experiments, the rate of axonal regeneration was determined by radiolabeling the L5 dorsal root ganglion. Regeneration rate for sensory axons was maximally increased (by 34%) in the 5-mg/kg group. In contrast, cyclosporin A (10 or 50 mg/kg; dosages were selected on the basis of the <FR><NU>1</NU><DE>10</DE></FR> lower potency of cyclosporin A) did not significantly alter the rate of axonal regeneration. Cyclosporin A (50 mg/kg) also failed to increase functional recovery or axonal calibers in the soleus nerve. Because the two drugs share a common mechanism for producing immunosuppression (i.e., calcineurin inhibition), these results indicate that FK506's nerve regenerative property involves a distinct, calcineurin-independent mechanism.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 ChestHome page
A. G. Duarte, L. Terminella, J. T. Smith, A. C. Myers, G. Campbell, and S. Lick
Restoration of Cough Reflex in Lung Transplant Recipients
Chest, August 1, 2008; 134(2): 310 - 316.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
Y. A. Pan, T. Misgeld, J. W. Lichtman, and J. R. Sanes
Effects of Neurotoxic and Neuroprotective Agents on Peripheral Nerve Regeneration Assayed by Time-Lapse Imaging In Vivo
J. Neurosci., December 10, 2003; 23(36): 11479 - 11488.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
W. P. Revill, J. Voda, C. R. Reeves, L. Chung, A. Schirmer, G. Ashley, J. R. Carney, M. Fardis, C. W. Carreras, Y. Zhou, et al.
Genetically Engineered Analogs of Ascomycin for Nerve Regeneration
J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1278 - 1285.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. W. Jones, S. A. Gruber, J. H. Barker, W. C. Breidenbach, and The Louisville Hand Transplant Team
Successful Hand Transplantation -- One-Year Follow-Up
N. Engl. J. Med., August 17, 2000; 343(7): 468 - 473.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. V. Shirbacheh, J. W. Jones, T. A. Harralson, J. Edelstein, T. Tecimer, W. C. Breidenbach, A. W. Jevans, C. Maldonado, J. H. Barker, and S. A. Gruber
Pharmacokinetics of Intra-arterial Delivery of Tacrolimus to Vascularly Isolated Rabbit Forelimb
J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1196 - 1201.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
B. G. Gold, V. Densmore, W. Shou, M. M. Matzuk, and H. S. Gordon
Immunophilin FK506-Binding Protein 52 (Not FK506-Binding Protein 12) Mediates the Neurotrophic Action of FK506
J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1202 - 1210.
[Abstract] [Full Text]

Home page
 J Hand Surg Eur VolHome page
H. FANSA, G. KEILHOFF, S. ALTMANN, K. PLOGMEIER, G. WOLF, and W. SCHNEIDER
The Effect of the Immunosuppressant FK 506 on Peripheral Nerve Regeneration Following Nerve Grafting
J Hand Surg Eur Vol., February 1, 1999; 24(1): 38 - 42.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.